Pelthos Therapeutics Inc.
PTHSAMEXHealthcare● Active
$26.62
+$1.07(+4.19%)
Market Cap$17263097
P/E Ratio—
52W High$54.29
52W Low$10.6
Pelthos Therapeutics Inc. (PTHS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PTHS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $16.80M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $9.37M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $7.43M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Margin %(computed) | 44.24% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $1.23M | $1.18M | $2.58M | $0.39M | $0.21M |
| G&A Expenses | $29.28M | $6.39M | $4.28M | $1.93M | $0.63M |
| Total Operating Expenses | $39.86M | $7.57M | $6.86M | $2.32M | $0.84M |
| Operating Income | ($32.43M) | ($7.57M) | ($6.86M) | ($2.32M) | ($0.84M) |
| Operating Margin %(computed) | -193.09% | — | — | — | — |
| Interest Income | $0.01M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $3.01M | $0.79M | $0.52M | $0.14M | $0.00M |
| Income Before Tax | ($50.71M) | ($7.96M) | ($7.38M) | ($2.46M) | ($0.60M) |
| Income Tax Expense | ($7.39M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($43.32M) | ($7.96M) | ($7.38M) | ($2.46M) | ($0.60M) |
| Net Margin %(computed) | -257.93% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-23.04 | $-13.54 | $-12.80 | $-4.26 | $-1.00 |
| Wtd Avg Shares | 1.88M | 0.59M | 0.58M | 0.58M | 0.58M |
| EBITDA | ($45.41M) | ($7.17M) | ($6.86M) | ($2.32M) | ($0.60M) |
| EBITDA Margin %(computed) | -270.37% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Pelthos Therapeutics Inc. data
About Pelthos Therapeutics Inc. (PTHS) Income Statement
Pelthos Therapeutics Inc. (PTHS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PTHS reported revenue of $0.02B, gross profit of $0.01B (gross margin 44.24%), and net income of ($0.04B) — a net profit margin of -257.93%.
Frequently asked questions
PTHS · 4 questionsPelthos Therapeutics Inc. (PTHS) reported revenue of $0.02B for 2025, up —% year-over-year.
PTHS revenuePTHS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09